Saccharomyces boulardii'. A Review of an Innovative Biotherapeutic Agent

References

• Adam J, Barret A, Barret-Bellet C, et al. Essais cliniques contrôlés en double insu de l'ultra-levure lyophilisée. Étude multicentrique par 25 médecins de 388 cas. Gazette Medicale de France 1977; 84: 2072–2078
   Google Scholar
• Aronsson B, Molby R, Nord CE. Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden. Journal of Infectious Diseases 1985; 151: 476–481
   PubMed Web of Science ®Google Scholar
• Bartlett JG. Antibiotic-associated diarrhea. Clinical Infectious Diseases 1992; 15: 573–581
   PubMed Web of Science ®Google Scholar
• Berg R, Bernasconi P, Fowler D, Gautreaux M. Inhibition of Candida albicans translocation from the gastrointestinal tract of immunosuppressed mice by oral treatment with Saccharomycesboulardii. Journal of Infectious Diseases 1993, (in press)
   Google Scholar
• Blehaut H, Massot J, Elmer GW, Levy RH. Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharmaceutics &Drug Disposition 1989; 10: 353–364
   PubMed Web of Science ®Google Scholar
• Blehaut H, Saint-Marc T, Touraine JL. Double blind trial of Saccharomyces boulardii in AIDS related diarrhe a. Abstract No. 2120, VIII International Conference on AIDS/III STD World Congress. 1992, 19–24 July, 1992
   Google Scholar
• Boddy AV, Elmer GW, McFarland LV, Levy RH. Influence of antibiotics on the recovery and kinetics of Saccharomyces boulardii in rats. Pharmaceutical Research 1991; 8: 796–800
   Web of Science ®Google Scholar
• Bowden TA, Mansberger AR, Lykins LE. Pseudomembraneous enterocolitis: mechanism of restoring floral hemeostasis. American Surgeon 1982; 4: 178–183
   Google Scholar
• Buts J-P, Bernasconi P, Van Craynest M-P, Maldague P, De Meyer R. Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatric Research 1986; 20: 192–196
   PubMed Web of Science ®Google Scholar
• Buts J-P, Bernasconi P, Vaerman J-P, Dive C. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Digestive Diseases and Sciences 1990; 35: 251–256
   PubMed Web of Science ®Google Scholar
• Buts J-P, Corthier G, Delmee M. Saccharomyces boulardii for Clostridium difficile associated enteropathies in infants. Journal of Pediatric Gastroenterology and Nutrition 1993, (in press)
   Web of Science ®Google Scholar
• Caetano JA, Parames MT, Babo MJ, Santos A, Ferreira AB, Freitas AA, Coelho MRC, Mateus AM. Immunopharmacological effects of Saccharomyces boulardii in healthy human volunteers. International Journal of Immunopharmacology 1986; 8: 245–259
   Web of Science ®Google Scholar
• Cano N, Chapoy P, Corthier G. Saccharomyces boulardii: un traitement des colites pseudomembraneuses?. Presse Medicate 1989; 18: 1299
   Google Scholar
• Castex F, Jouvert S, Bastide M. Visualisation par microscopie électronique à balayage du transit intestinal de Saccharomyces boulardii chez la souris. Bulletin de la Société Française de Mycologie Medicate 1987; 16: 249–256
   Google Scholar
• Castex F, Corthier G, Jouvert S, Elmer GW, Guibal J, Lucas F, Bastide M. Prevention of experimental pseudomembranous cecitis by Saccharomyces boulardii. topographical histology of the mucosa, bacterial counts, and analysis of toxin production. Microecology and Therapy, SJ Dougherty, DJ Hentges, DM Lyerly, et al. Institute for Microbiology, Herborn-Dill 1989; Vol 19: 241
   Google Scholar
• Castex F, Corthier G, Jouvert S, Elmer GW, Lucas F, Bastide M. Prevention of Clostridium difficile-induced experimental pseudomembranous colitis by Saccharomyces boulardii: a scanning electon microscopic and microbiological study. Journal of General Microbiology 1990; 136: 1085–1089
   Google Scholar
• Cetina-Sauri G, Basto GS. Evaluation terapéutica de Saccharomyces boulardii en niños con diarrea aguda. Tribuna Médica 1989; 56: 111–115
   Google Scholar
• Chapoy P. Traitement des diarrhées aiguës infantiles: essai contrôlé de Saccharomyces boulardii. Annales de Pédiatrie (Paris) 1985; 32: 561–563
   Google Scholar
• Corthier G, Dubos F, Ducluzeau R. Prevention of Clostridium difficile induced mortality in gnotobiotic mice by Saccharomyces boulardii. Canadian Journal of Microbiology 1986; 32: 894–896
   PubMed Web of Science ®Google Scholar
• Corthier G, Dubos-Ramare F, Muller MC, Mahé S, Vernet A, Elmer GW, Rapine P, Ducluzeau R. Étude expérimentale, chez les souris à flore contrôlée, des moyens écologiques de lutte contre la pathologie due à Clostridium difficile. Clostridium difficile-associated Intestinal Diseases, J-C Rambaud, R Ducluzeau. Springer-Verlag, Paris 1990; 105–113
   Google Scholar
• Corthier G, Lucas R, Jouvert S, Castex F. Effect of oral Saccharomyces boulardii treatment on the activity of Clostridium difficile toxins in mouse digestive tract. Toxicon 1992; 30: 1583–1589
   Web of Science ®Google Scholar
• Czerucka D, Nano JL, Bernasconi P, Rampal P. Réponse à la toxine cholérique de deux lignées de cellules épitheliales intestinales. Effet de Saccharomyces boulardii. Gastroenterologie Clinique et Biologique 1989; 13: 383–387
   PubMedGoogle Scholar
• Czerucka D, Nano JL, Bernasconi P, Rampal P. Réponse aux toxines A et B de Clostridium difficile d'une lignée de cellules épithéliales intestinales de rat: IRD 98. Effet de Saccharomyces boulardii. Gastroenterologie Clinique et Biologique 1991; 15: 22–27
   Google Scholar
• Czerucka D, Roux I, Nano JL, Bernasconi P, Rampal P. In vitro, antidiarrheic effect of yeast Saccharomyces boulardii. Abstract No. 709. Gastroenterology 1992; 102: A207
   Google Scholar
• Czerucka D, Roux I, Rampal P. The cholera toxin neutralizing factor secreted by Saccharomyces, boulardü acts directly on cells. Abstract No. 1087. Gastroenterology 1993, (in press)
   Web of Science ®Google Scholar
• Drapkin MS, Worthington MG, Chang TW, Razvi SA. Clostridium difficile colitis mimicking acute peritonitis. Archives of Surgery 1985; 120: 1321–1322
   PubMedGoogle Scholar
• Ducluzeau R, Bensaada M. Effet comparé de l'administration unique ou en continu de Saccharo-myces boulardii sur l'établissement de diverses souches de Candida dans le tractus digestif de souris gnotoxéniques. Annales de Microbiologie (Paris) 1982; 133: 491–501
   PubMedGoogle Scholar
• Dudley MN, McLaughlin JC, Carrington G, Frick J, Nightingale CH, Quintiliani R. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea: a randomized double-blind trial. Archives of Internal Medicine 1986; 146: 1101–1104
   PubMedGoogle Scholar
• Elmer GW, McFarland LV. Suppression by Saccharomyces boulardüi of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters. Antimicrobial Agents and Chemotherapy 1987; 31: 129–131
   PubMed Web of Science ®Google Scholar
• Elmer GW, Surawicz CM, McFarland LV, Chinn J. An open trial of vancomycin plus Saccharomyces boulardü for the treatment of relapsing Clostridium difficile diarrhea/colitis. Microecology and Therapy, SH Dougherty, DJ Hentges, DM Lyerly, et al. Institute for Microecology, Herborn-Dill 1989; Vol. 19: 251
   Google Scholar
• Elmer GW, Corthier G. Modulation of Clostridium difficile induced mortality as a function of the dose and the viability of the Saccharomyces boulardü used as a preventative agent in gnotobiotic mice. Canadian Journal of Microbiology 1991; 37: 315–317
   PubMed Web of Science ®Google Scholar
• Fekety R, Shah AB. Diagnosis and treatment of Clostridium difficile colitis. Journal of the A merican Medical Association 1993; 289: 71–75
   Google Scholar
• Gerberding JL. Diagnosis and management of HIV-infected patients with diarrhoea. Journal of Antimicrobial Chemotherapy 1989; 23(Suppl. A)83–87
   Google Scholar
• Gerding DN. Disease associated with Clostridium difficile infection. Annals of Internal Medicine 1989; 110: 255–257
   PubMed Web of Science ®Google Scholar
• Giudici HJ, Botto L, Montejo de Aramayo IA, Aramayo L. Evaluatión clinica de la administratión de Saccharomyces boulardü “Vitales” en el tratamiento de la diarrea aguda en ninos. Informe preliminar. La Semana Medica 1985; 167: 254–262
   Google Scholar
• Gorbach SL, Chang T-W, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancetü 1987; 1519
   Google Scholar
• Grillot R, Lebeau B, Goullier-Fleuret A, Chouraqui JP, Andrini P. “De deux maux il faut choisir le moindre” ou du caractere opportuniste de Saccharomyces boulardü. Abstrac t. Royale Société Française de Mycologie Médicale. ParisFrance 1986
   Google Scholar
• Guenter PA, Settle RG, Perlmutter S, Marino PL, Desimone GA, Rolandelli RH. Tube feeding-related diarrhea in acutely ill patients. Journal of Par enter al Enteral Nutrition 1991; 15: 277–280
   PubMed Web of Science ®Google Scholar
• Höchter W, Chase D, Hagenhoff G. Saccharomyces boulardü bei akuter erwachsenendiarrhoe. Wirksamkeit und verträglichkeit der behandlung. Münchener Medizinische Wochenschrift 1990; 132: 188–192
   Google Scholar
• Johnson S, Gerding DN, Olson MM, Weiler MD, Hughes RA, Clabots CR, Peterson LR. Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. American Journal of Medicine 1990; 88: 137–140
   PubMed Web of Science ®Google Scholar
• Jouirou A, Jeridi A, Ben Said H, El Mabrouk J, Essoussi AS, Harbi A. Le traitement des diarrhees aigues du nourrisson: place de Saccharomyces boulardü. Maghreb Medical 1990; 229: 29–31
   Google Scholar
• Kabins SA. Outbreak of clindamycin-associated colitis. Annals of Internal Medicine 1975; 83: 830–831
   PubMed Web of Science ®Google Scholar
• Kimmey MB, Elmer GW, Surawicz CM, McFarland LV. Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardü. Digestive Diseases and Sciences 1990; 35: 897–901
   Web of Science ®Google Scholar
• Klein SM, Elmer GW, McFarland LV, Surawicz CM, Levy RH. Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardü, in healthy human volunteers. Pharmaceutical Research 1993, (in press)
   Web of Science ®Google Scholar
• Krause W, Matheis H, Wulf K. Fungaemia and funguria after oral administration of Candida albicans. Lancet i 1969; 598: 600
   Google Scholar
• Levecq H, Cerf H. Intérět des levures et des lactobacilles dans le traitement préventif ou curatif des diarrhées post-antibiotiques et au cours du sida. EMC—Instantanés Médicaux 1992; 5: 3–5
   Google Scholar
• Machado Caetano JA, Parames MT, Babo MJ, Santos A, Bandeira Ferreira A, Freitas AA, Clementa Coelho MR, Matthioli Mateus A. Immunopharmacological effects of Saccharomyces boulardü in healthy volunteers. International Journal of Immunopharmacology 1986; 8: 245–249
   PubMed Web of Science ®Google Scholar
• Marteau P, Pochart P, Flourie B, Pellier P, Santos L, Desjeux J-F, J-C. Rambaud. Effect of chronic ingestion of a fermented dairy product containing Lactobacillus acidophilus, Bifidobacterium bifidum on metabolic activities of the colonic flora in humans. American Journal of Clinical Nutrition 1990; 52: 685–688
   PubMed Web of Science ®Google Scholar
• Massot J, Desconclois M, Astoin J. Protection par Saccharomyces boulardü de la diarrhée à Escherichia coli du souriceau. Annales Pharmaceutiques Francoises 1983; 40: 445–449
   Google Scholar
• Massot J, Sanchez O, Couchy R, Astoin J, Parodi AL. Bakteriopharmakologische aktivitat von Saccharomyces boulardü bei der clindamycin-induzierten kolitis im hamster. Arzneimittel-Forschung 1984; 34: 794–797
   PubMed Web of Science ®Google Scholar
• McFarland LV, Mulligan ME, Kwok RYY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. New England Journal of Medicine 1989; 320: 204–210
   PubMed Web of Science ®Google Scholar
• McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. Journal of Infectious Diseases 1990; 162: 678–684
   PubMed Web of Science ®Google Scholar
• McFarland LV. The epidemiology of Clostridium difficile infections. Gastroenterology International 1991; 4: 82–85
   Google Scholar
• McFarland LV, Surawicz CM, Elmer GW, Moyer KA, Melcher SA, Greenberg R, Bowen K. Multivariate analysis of the clinical efficacy of a biotherapeutic agent, Saccharomyces boulardü, for the prevention of antibiotic-associated diarrhea. Abstract No. 148. American Journal of Epidemiology 1993, (in press)
   Web of Science ®Google Scholar
• Mulligan ME, Citron D, Gabay E, Kirby B, George WL, Finegold SM. Alterations in human fecal flora, including ingrowth of Clostridium difficile, related to cefoxitin therapy. Antimicrobial Agents and Chemotherapy 1984; 26: 343–346
   PubMed Web of Science ®Google Scholar
• Pierce PF, Wilson R, Silva J, Garagusi VF, Rifkin D, Fekety R, Nunez-Montiel O, Dowell VR, Hughes JM. Antibiotic associated pseudo-membranous colitis: an epidemiologic investigation of a cluster of cases. Journal of Infectious Diseases 1982; 145: 169–174
   Web of Science ®Google Scholar
• Pothoulakis C, Kelly CP, Joshi MA, Gao N, O'Keane CJ, Castagliuolo I, LaMont JT. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 1993, (in press)
   Web of Science ®Google Scholar
• Rao SSC, Edwards CA, Austen CJ, Bruce C, Read NW. Impaired colonic fermentation of carbohydrate after ampicillin. Gastroenterology 1988; 94: 928–932
   PubMed Web of Science ®Google Scholar
• Read NW. Diarrhoea: the failure of colonic salvage. Lancet 1982; ii: 481–483
   Google Scholar
• Rigothier MC, Maccario J, Vuong PN, Gayral P. Effets des levures Saccharomyces boulardii sur les trophozoïtes d'Entamoeba histolylica in vitro et dans l'amibiase caecale du jeune rat. Annales de Parasitologie Humaine et Comparee 1990; 65: 51–60
   Google Scholar
• Saint-Marc T, Rossello-Prats L, Touraine JL. Efficacité de Saccharomyces boulardii dans le traitement des diarrhées du SIDA. Annales de Medecine Interne (Paris) 1991; 142: 64–65
   PubMedGoogle Scholar
• Schlotterer M, Bernasconi P, Lebreton F, Wassermann D. Interet de Saccharomyces boulardii dans la tolerance digestive de la nutrition entérale à débit continu chez le brûlé. Nutrition Clinique et Métabolisme 1987; I: 31–34
   Google Scholar
• Siitonen S, Vapaatalo H, Salminen S, Gordin A, Saxelin M, Wikberg R, Kirkkola A-L. Effect of Lactobacillus GG yoghurt in prevention of antibiotic associated diarrhoea. Annals of Medicine 1990; 22: 57–59
   PubMed Web of Science ®Google Scholar
• Smith CE, Marien L, Brogdon C, Faust-Wilson P, Lohr G, Gerald KB, Pingleton S. Diarrhea associated with tube feeding in mechanically ventilated critically ill patients. Nursing Research 1990; 39: 148–152
   Web of Science ®Google Scholar
• Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, Van Belle G. A clinical trial to test the ability of Saccharomyces boulardii to prevent antibiotic associated diarrhoea. Microecology and Therapy, VD Bokkenheuser, SP Borriello, G Donelli, et al. Institute for Microecology, Herborn-Dill 1988; Vol. 18: 113
   Google Scholar
• Surawicz CM, McFarland LV, Elmer G, Chinn J. Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. American Journal of Gastroenterology 1989; 84: 1285–1287
   PubMed Web of Science ®Google Scholar
• Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, Van Belle G. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989; 96: 981–988
   PubMed Web of Science ®Google Scholar
• Surawicz CM, Greenberg R, Fekety R, McFarland LV, Moyer K, Bowen K, Cox J, Noorani Z, Elmer GW. Saccharomyces boulardii prevents recurrent C. difficile pseudomembranous colitis and diarrhea: a multicenter controlled trial. Abstract No. 57–0015. Gastroenterology 1993, (in press)
   Google Scholar
• Tankanow RM, Ross MB, Ertel IJ, Dickinson DG, McCormick LS, Garfinkel JF. A double-blind, placebo-controlled study of the efficacy of lactinex in the prophylaxis of amoxicillin-induced diarrhea. DICP, The Annals of Pharmacotherapy 1990; 24: 382–384
   PubMedGoogle Scholar
• Teasley PG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ, Lee JT, Jr. Prospective randomized trial of metronidazole versus vancomycin for Clostridium difficile-associaied diarrhea and colitis. Lancet 1983; ii: 1043–1046
   Google Scholar
• Tedesco RJ, Barton RW, Alpers DH. Clindamycin-associated colitis. Annals of Internal Medicine 1974; 81: 429–433
   PubMed Web of Science ®Google Scholar
• Tempé JD, Steidel AL, Blehaut H, Hasselmann M, Lutun PH, Maurier F. Prevention par Saccharomyces boulardii des diarrhées de l'alimen-tation entérale a débit continu. La Semaine des Hôpitaux de Paris 1983; 59: 1409–1412
   PubMedGoogle Scholar
• Toothaker RD, Elmer GW. Prevention of clindamycin-induced mortality in hamsters by Saccharomyces boulardii. Antimicrobial Agents and Chemotherapy 1984; 26: 552–556
   PubMed Web of Science ®Google Scholar
• Van der Waaij D, Horstra H, Wiegersma N. Effect of β-lactam antibiotics on the resistance of the digestive tract of mice to colonization. Journal of Infectious Diseases 1982; 146: 417–422
   Web of Science ®Google Scholar
• Vidon N, Huchet B, Rambaud JC. Influence de Saccharomyces boulardii sur la sécrétion jéjunale induite chez le rat par la toxinc cholérique. Gastraenterologie Clinique et Biologique 1986; 10: 13–16
   PubMedGoogle Scholar
• Vincent P, Colombel JF, Lescut D, Fournier L, Savage C, Cortot A, Quandalle P, Vankemmel M, Leclerc H. Bacterial translocation in patients with colorectal cancer. Journal of Infectious Diseases 1988; 158: 1395–1396
   Web of Science ®Google Scholar
• Wilmore DW. Nutrition and metabolism following thermal injury. Clinics in Plastic Surgery 1974; 1: 603
   Google Scholar
• Zunic P, Lacotte J, Pegoix M, Buteux G, Leroy G, Mosquet B, Moulin M. Fongémie a Saccharomyces boulardii. A propos d'un cas (letter). Therapie 1991; 46: 498–199
   PubMed Web of Science ®Google Scholar